Home › Kidney Cancer (Renal Cell Carcinoma) › Ohio
Kidney Cancer (Renal Cell Carcinoma) clinical trials in Ohio
26 studies for Kidney Cancer (Renal Cell Carcinoma) are looking for participants at sites in Ohio.
Cities in Ohio
- Cleveland14 studies
- Columbus13 studies
- Akron5 studies
- Cincinnati5 studies
- Dayton5 studies
- Toledo3 studies
- Parma3 studies
- Youngstown3 studies
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, Cleveland
- Research Site, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05536141Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- NEO-811 Cleveland Site, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07300241A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06234605Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- and 44 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #10, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Strecker Cancer Center-Belpre, Belpre
- Adena Regional Medical Center, Chillicothe
- Ohio State University Comprehensive Cancer Center, Columbus
- and 22 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 29, 2026 · NCT04981509DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- The Ohio State University Comprehensive Cancer Center, Columbus
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- Local Institution - 0135, Cincinnati
- Cleveland Clinic, Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07293351Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
- Ohio State University Comprehensive Cancer Center, Columbus
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06863311Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Miami Valley Hospital South, Centerville
- and 13 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05327686ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Aultman Health Foundation, Canton
- and 10 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06661720Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
- University Hospitals Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05361720Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Cleveland Clinic, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06966024Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, Cincinnati
- Xencor Investigative Site, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05433142A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- James Cancer Hospital and Solove Research Institute, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT03972657KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Ohio State University, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT06026410Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
- Cleveland Clinic, Cleveland
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 8, 2026 · NCT05363280Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- The Ohio State University Wexner Medical Center, Columbus
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Mar 9, 2026 · NCT04792463Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Gabrail Cancer & Research Center, Canton
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT05856981A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- Case Comprehensive Cancer Center, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2025 · NCT06805825A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- The Ohio State University, Columbus
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT06682793Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Indu and Raj Soin Medical Center, Beavercreek
- and 20 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT04510597A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Cleveland Clinic, Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 25, 2024 · NCT05824975From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.